Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04710498 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT04710498: Completed Phase 2 study, sponsored by Stanford University.
NCT04710498 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04710498, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this research is to evaluate whether the administration of atezolizumab before surgical resection of the tumor is feasible and to evaluate the treatment response, safety, and tolerability of atezolizumab.
Interventions
- DRUG Atezolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-06-22 |
| Est. Completion | 2024-02-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04710498
The ClinicalTrials.gov registry entry for NCT04710498 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atezolizumab is the first listed.
NCT04710498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04710498 about?
NCT04710498 is a clinical study titled "Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma". The purpose of this research is to evaluate whether the administration of atezolizumab before surgical resection of the tumor is feasible and to evaluate the treatment response, safety, and tolerability of atezolizumab.
What is the current status of trial NCT04710498?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2021-06-22. Estimated completion is 2024-02-15.
What interventions are being tested in trial NCT04710498?
The interventions under investigation include: Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT04710498?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.